Collegium Pharmaceutical Analyst Price Targets

Wall Street analyst price targets and consensus rating for Collegium Pharmaceutical (COLL).

Price Target Range — 10 Quarters

Analyst Consensus — 8 Analysts

7Buy

1Hold

Consensus RatingBuy# Analysts8Avg. Consensus PT$47Upside to Avg. PT+116.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	Oppenheimer	Les Sulewski	Initiate	Outperform	$50
Sep 9, 2026	Truist Securities	Alexander Xenakis	PT Cut	Buy	$58→$49
Sep 9, 2026	Leerink Partners	Daniel Clark	Initiate	Outperform	$45
Aug 19, 2026	Barclays	Glen Santangelo	PT Cut	Overweight	$56→$48
Aug 7, 2026	Piper Sandler	David Amsellem	PT Cut	Neutral	$45→$43
Aug 6, 2026	Needham	Serge Belanger	PT Cut	Buy	$56→$46
Mar 20, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$60
Mar 19, 2026	Needham	Serge Belanger	PT Raise	Buy	$54→$56
Feb 26, 2026	Needham	Serge Belanger	PT Cut	Buy	$56→$54
Jan 9, 2026	Barclays	Glen Santangelo	PT Cut	Overweight	$58→$56
Jan 9, 2026	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$46→$60
Jan 8, 2026	Needham	Serge Belanger	PT Raise	Buy	$48→$56
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Overweight	$58
Nov 7, 2025	Truist Securities	Les Sulewski	PT Raise	Buy	$45→$48
Nov 7, 2025	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$44→$46
Oct 28, 2025	Needham	Serge Belanger	Maintained	Buy	$46
Aug 11, 2025	HC Wainwright & Co.	Brandon Folkes	Assumes	Buy	$44
May 9, 2025	Piper Sandler	David Amsellem	PT Raise	Neutral	$36→$37
Apr 9, 2025	Needham	Serge Belanger	Maintained	Buy	$46
Mar 24, 2025	HC Wainwright & Co.	Oren Livnat	Maintained	Buy	$50

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50

Oppenheimer analyst Les Sulewski initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $50.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $49

Truist Securities analyst Alexander Xenakis maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $58 to $49.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $45

Leerink Partners analyst Daniel Clark initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $45.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48

Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $56 to $48.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43

Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $45 to $43.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46

Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $56 to $46.

Benzinga Newsdesk

Collegium Pharmaceutical Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Collegium Pharmaceutical Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50

PRO
Truist Securities Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $49

PRO
Leerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $45

PRO
Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48

PRO
Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43

PRO
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46

People Also Watch

People Also Watch

Collegium Pharmaceutical Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Collegium Pharmaceutical Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROOppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50

PROTruist Securities Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $49

PROLeerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $45

PROBarclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48

PROPiper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43

PRONeedham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46

People Also Watch

People Also Watch

PRO
Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50

PRO
Truist Securities Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $49

PRO
Leerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $45

PRO
Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48

PRO
Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43

PRO
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46